Genetic association studies to detect adverse drug reactions: Abacavir hypersensitivity as an example

Pharmacogenomics

Volumn 10, Issue 2, 2009, Pages 225-233

  Hughes, Arlene R ^a   Brothers, Cynthia H ^b   Mosteller, Michael ^a   Spreen, William R ^c   Burns, Daniel K ^a  

^a GLAXOSMITHKLINE   (United States)

^b Infectious Diseases Medicines Development Centre   (United States)

^c Infectious Diseases Centre of Excellence in Drug Discovery   (United States)

Author keywords

Abacavir; Drug safety; HLA B*5704; Hypersensitivity; Pharmacogenetics

Indexed keywords

ABACAVIR; ATAZANAVIR; DRUG METABOLIZING ENZYME; HLA B ANTIGEN; RITONAVIR; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; HLA B*5701 ANTIGEN, HUMAN; HLA-B*5701 ANTIGEN, HUMAN; RNA DIRECTED DNA POLYMERASE INHIBITOR;

CLINICAL PRACTICE; CLINICAL TRIAL; DNA SCREENING; DRUG DETERMINATION; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MARKETING; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; FATIGUE; GENE IDENTIFICATION; GENE LOCATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; IMMUNOGENETICS; MALAISE; PATCH TEST; PHARMACOGENETICS; PHENOTYPE; REIMBURSEMENT; REVIEW; GENETICS; METHODOLOGY; MORTALITY; PROSPECTIVE STUDY; RETROSPECTIVE STUDY;

DIDEOXYNUCLEOSIDES; DRUG HYPERSENSITIVITY; HLA-B ANTIGENS; HUMANS; PHENOTYPE; PROSPECTIVE STUDIES; RESEARCH DESIGN; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 65549125416     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.10.2.225     Document Type: Review

References (27)

1. Hughes AR, Spreen WR, Mosteller M et al.: Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility. Pharmacogenomics J. 8(6), 365-374 (2008).
2. Hetherington S, McGuirk S, Powell G et al.: Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin. Ther. 23, 1603-1614 (2001).
3. Cutrell AG, Hernandez JE, Fleming JW et al.: Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir. Ann. Pharmacother. 38, 2171-2172 (2004).
4. Hetherington S, Hughes AR, Mosteller M et al.: Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359, 1121-1122 (2002).
5. Mallal S, Nolan D, Witt C et al.: Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359, 727-732 (2002).
6. Hughes AR, Mosteller M, Bansal AT et al.: Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 5, 203-211 (2004).
7. Warren LL, Hughes AR, Lai EH et al.: Use of pairwise marker combination and recursive partitioning in a pharmacogenetic genome-wide scan. Pharmacogenomics J. 7, 180-189 (2007).
8. DeJesus E, Herrera G, Teofilo E et al.: Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin. Infect. Dis. 39, 1038-1046 (2004).
9. Staszewski S, Keiser P, Montaner J et al.: Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. JAMA 285, 1155-1163 (2004).
10. Gulick RM, Ribaudo Hj, Shikuma CM et al.: Triple-nucleoside regimens versus cfavirenz-containing regimens for the initial treatment of HIV-1.infection. N. Engl. J. Med. 350, 1850-1861 (2004).
11. Phillips EJ, Sullivan JR, Knowles SR, Shear NH: Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. AIDS 16, 2223-2225 (2002).
12. Phillips EJ, Wong GA, Kaul R et al.: Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS 19, 979-987 (2005).
13. Shear NH, Milpied B, Bruynzeel DP, Phillips EJ: A review of drug patch testing and implications for HIV clinicians. AIDS 22, 999-1007 (2008).
14. Rauch A, Nolan D, Martin A, McKinnon E, Almeida C, Mallal S: Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort. Clin. Infect. Dis. 43, 99-102 (2006).
15. Reeves I, Churchill D, Fisher M: Screening for HLA-B*5701 reduces the frequency of abacavir hypersensitivity reactions. Antivir. Ther. 11, L11 (2006).
16. Zucman D, de Truchis P, Majerholc C, Stegman S, Caillat-Zucman S: Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J. Acquir. Immune Defic. Syndr. 45, 1-3 (2007).
17. Hughes S, Hughes A, Brothers C, Spreen W, Thorborn D: PREDICT-1 (CNA106030): The first, powered, prospective trial of pharmacogenetic screening to reduce drug adverse events. Pharm. Stat. 7(2), 121-129 (2008).
18. Mallal S, Phillips E, Carosi G et al.: HLA-B*5701 screening for hypersensitivity abacavir. N. Engl. J. Med. 358, 568-579 (2008).
19. Brothers C, Wannamaker P, Sutherland-Phillips D, Hernandez J: Lower reported race of suspected hypersensitivity reactions (HSR) to abacavir (ABC) among black patients. Presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA, USA, 27-30 September (2006) (Abstract H-1065).
20. Middleton D, Menchaca L, Rood H, Kemerofsky R: New allele frequency databas http://ww-w.allelefrequencies.net. Tissue Antigens 61, 403-407 (2003).
21. Saag M, Balu R, Phillips E et al.: High sensitivity of human leukocyte antigen-B*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin. Infect. Dis. 46, 1111-1118 (2008).
22. Young B, Squires K, Patel P et al.: First large multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America. AIDS 22, 1673-1675 (2008).
23. Faraki H, Heine U, Brown T et al.: HLA-B*5701 clinical testing: early experience in the United States. Pharmacogenet. Genomics 17, 857-860 (2007).
24. Roses AD: Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat. Rev. Genet. 5, 645-656 (2004).
25. Hughes DA, Vilar FJ, Ward CC et al.: Cost-effectiveness analysis of HLA-B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 14, 335-342 (2004).
26. Schackman BR, Scott CA, Walensky RP et al.: Genetic testing in HIV care: clinical impact and cost-effectiveness of HLA-B*5701 screening to guide first-line abacavir use. Presented at: 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, February 3-6 (2008) (Poster 911).
27. Farkouh R, Earnshaw SR, Kauf TL et al.: Cost-effectiveness of HLA-B*5701 testing prior to initaiton of abacavir sulfate. Presented at: 18th International AIDS Conference. Mexico City, Mexico, August 3-8 (2008) (Poster P9329).